## Journal of

#### Gastroenterology and Hepatology Research

Online Submissions: http://www.ghrnet.org/index./joghr/doi:10.6051/j.issn.2224-3992.2014.03.434

Journal of GHR 2014 November 21 3(11): 1326-1327 ISSN 2224-3992 (print) ISSN 2224-6509 (online)

**REVIEW** 

# Helicobacter pylori Infection and Asthma

#### Amin Talebi Bezmin Abadi

Amin Talebi Bezmin Abadi, Department of Medical Microbiology, University Medical Center Utrecht (UMCU), Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands

Correspondence to: Amin Talebi Bezmin Abadi, Department of Medical Microbiology, University Medical Center Utrecht (UMCU), Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands

Email: Amin.talebi@gmail.com

Telephone:+887556507 Fax:+887555426 Received: April 26, 2014 Revised: May 19, 2014

Accepted: Mya 22, 2014

Published online: November 21, 2014

## **ABSTRACT**

There is an indication of associated extragastric diseases such as asthma with *H. pyloriv* infection. Asthma is one of the most common chronic disorders in both childhood and adults, characterized with symptoms of wheezing and shortness of breath brought about by airway inflammation and obstruction. Complex human immune responses are involved in the pathogenesis of asthma. Meanwhile, *H. pyloriv* colonization seems to be effectively engaged. As result, *H. pyloriv* infection can provide protection against asthma. Optimistically, *H. pyloriv* status can be an informative biomarker for asthma especially in children. Detecting and applying the *H. pyloriv* effective molecules affecting the immune response to divert asthma can be an optimal point in current research.

© 2014 ACT. All rights reserved.

Key words: Helicobacter pylori; Asthma

Talebi Bezmin Abadi A. *Helicobacter pylori* Infection and Asthma. *Journal of Gastroenterology and Hepatology Research* 2014; 3(11): 1326-1327 Available from: URL: http://www.ghrnet.org/index.php/joghr/article/view/925

#### INTRODUCTION

At least 50% the world's population is infected with *Helicobacter pylori* (*H. pyloriv*), although only a minority of colonized individuals

develop severe digestive and extragastric disorders[1]. It has been indicated that association of H. pyloriv and extragastric diseases is an area of clinical microbiology which remains to be elucidated<sup>[2,3]</sup>. After the H. pyloriv colonization, a predominant activation of Th1 cells, with the subsequent production of IFN-y, IL-12, IL-18, IL-23 and TNF-α, occur in human gastric cells. The aforementioned immune response is addressed in the current report to elucidate its role in the pathogenesis of H. pyloriv-associated asthma. Asthma is one of the most common chronic disorders in both childhood and adults, characterized with symptoms of wheezing and shortness of breath brought about by airway inflammation and obstruction<sup>[4]</sup>. This chronic respiratory disease increases in importance as one considers that there are an estimated 300 million individuals affected worldwide. More recently, the severity and incidence of asthma in many developed countries has sharply increased<sup>[5]</sup>. To date, there is no generally agreed rationale concerning this mysterious increase in incidence, although some reports suggest an inverse link between (H. pyloriv) colonization and occurrence of asthma. H. pyloriv is an indigenous resident in the human stomach; and among the bacterium has the strongest known modulation of the human immune system to suppress effective response to its own infection. H. pyloriv has been recognized as a persistent pathogen that causes gastric ulcer and gastric cancer. As a general concept, H. pyloriv infection can provide protection against asthma. This leads to the important ongoing question of whether we should infect people (including not previously colonized individuals) to prevent asthma or not. Broadly defined, those severe diseases induced by the H. pyloriv infections usually occur later in life, while asthma is considered as highly prevalent respiratory diseases in children. Collectively, we are confronted with a dilemma concerning the strategies about *H. pyloriv* treatment in the case of asthma patients. After 50,000 years of biologic co-evolution of human and *H. pyloriv* an ability to coexist seems definite. A partial answer might be to not target all H. pyloriv strains for elimination lifelong. It also may be beneficial to consider the balance between extragastric disease appearance and infectious agent<sup>[5]</sup>. Hence, we can aim to deal with this problem according to the timing (early or later) in clinical symptoms. It is possible that we could first gain benefits from H. pyloriv colonization in childhood (Asthma prevention) and then later trying to eradicate it before peptic ulcers occurrence in adults.

Undoubtedly, more research is necessary to elucidate the exact mechanisms induced by H. pyloriv may prevent asthma development in children<sup>[3]</sup>. Undoubtedly, more research is necessary to elucidate the exact mechanisms induced by *H. pyloriy* that may prevent asthma development in children. Meanwhile, others believe that eradication of H. pyloriv infection is strongly beneficial for curing peptic ulcer disease, gastric MALT lymphoma (Mucosa associated lymphoid tissue) and for the prevention of gastric cancer, and that it must be done in all *H. pyloriv*-infected patients, whether they are asthmatic or not. Research which reports the effects of H. pyloriv on the human immune system proposes trying to use them synthetically rather than as live bacterium. This can be a novel idea to be applied in the medical setting. Potentially, we could use this novel molecule to treat asthma patients, while available guidelines to eradicate H. pyloriv are still followed by clinicians and gastroenterologist. Optimistically, H. pyloriv status can be an informative biomarker for asthma especially in children. Overall, future research should continue to determine the exact mechanism which defines the less harmless H. pyloriv strains, which can be altered in children to prevent asthma, can help to manage this rouge gastroduodenal bacterium.

## **REFERENCES**

- Cid TP, Fernandez MC, Benito Martinez S, Jones NL, Pathogenesis of Helicobacter pylori infection. Helicobacter 2013; 18: 12-17
- Franceschi F. and A. Gasbarrini, Helicobacter pylori and extragastric diseases. Best Practice & Research Clinical Gastroenterology 2007; 21: 325-334
- 3 Realdi G, Dore MP, Fastame L. Extradigestive Manifestations of Helicobacter pylori Infection (Fact and Fiction). Digestive diseases and sciences 1999; 44: 229-236
- 4 Eder W, Ege MJ, von Mutius E. The asthma epidemic. *N* Engl J Med 2006; **355**: 2226-2235
- 5 Chen Y and Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. Journal of infectious diseases 2008; 198: 553-560

**Peer reviewers:** Yuji Naito, Associate Professor, Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kamigyo-ku, Kyoto 602-8566, Japan; Stewart Stewart Day, Department of Paediatrics, University of Otago, Christchurch, P.O. Box 4345, Christchurch, 8140, New Zealand.